Immix Biopharma Investor Presentation Deck

N-GENIUS Technology Platform - NXC-201: First "Single-Day CRS" CAR-T - Narrow, Predictable Side Effect Window in Multiple Myeloma NXC-201 Johnson & Johnson CARVYKTI Iciltacabtagene autoleucell Median onset range of duration of CRS Median onset range of duration of ICANS neurotoxicity Side-Effect Window Baseline SBCMA -460,000 pg/mL Bristol Myers Squibb Median onset range of duration of CRS Median onset range of duration of ICANS neurotoxicity Side-Effect Window Abecma (idecabtagene vicleuce) Baseline SBCMA -500,000 pg/mL Baseline SBCMA -203,000 pg/mL Median onset range of duration of CRS Median onset range of duration of ICANS neurotoxicity 1 Side-Effect Window 1-7 CRS duration Zero neurotoxicity sBCMA AUC 田田 sBCMA AUC CAR-T cells CAR-T cells 30 days -40 CAR-T cells SBCMA area under the curve (AUC) CRS duration 1-63 CRS duration CAR-T cell expansion in the blood -Relative sBCMA tumor marker level in blood --Limit of Quantitation, sBCMA ICANS Neurotoxicity duration 2-297 60 days 田田田田田田 ICANS Neurotoxicity duration 1-578 田田田田田田田田田田田 NXC-201 Produces Deepening Response Transformations Day 200-240 After Treatment (median 5.7 months of follow-up as of Feb 9 2023 data cutoff) Pt. 23 Day 240 VGPR CR 10-5 Pt. 11 Day 225 VGPR MRD+ → VGPR MRD- Pt. 22 Day 200 VGPR → CR 10-5 155 days ... do 田田田田田田田 IMMIX BIOPHARMA 1 NXC-201: Max 7-day CRS Others: up to 63 day CRS 2 NXC-201: Low (4%) Neurotoxicity Others: Up to 578-day neurotoxicity 3 NXC-201: SBCMA reduced in -30 days Others: SBCMA reduced in -60-155 days 4 NXC-201: CAR-T cells exit body after sBCMA reduced Others: CAR-T cells remain elevated, causing 田田 ← Days since CAR-T cell infusion → *NXC-201: No measurements available beyond 30 days in multiple myeloma as of the Feb 2023 data cutoff (in human data from AL Amyloidosis, NXC-201 clears system in < 30days as seen on the next slide) 23 Source: FDA labels; company presentations; EMA assessment report; Asherie, N., et al. Haematologica, 2022. Frigault, M., et al. Blood Advances, 2022; Shen, Y, et al. Curr Res Transl Med. 2023; Janssen Science; Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies; Y-axes units (log10) for T-cell expansion: cells/mL blood (NXC-201) and vector transgene copies/ug of genomic DNA (Carvykti, Abecma), for relative SBCMA: 0-200 (NXC-201), ng/mL (Abecma) and pg/mL (Carvykti); Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. prolonged neurotoxicity and CRS

View entire presentation